Research & Innovation
Publications
Topical Diacerein Decreases Skin and Splenic CD11c + Dendritic Cells in Psoriasis.
PMU Authors
Susanne Brunner, Andrea Ramspacher, Michael Ablinger, Julia Tevini, Monika Wimmer, Andreas Koller, Josefina Piñón Hofbauer, Thomas Felder, Johann Bauer, Barbara Kofler, Roland Lang, Verena Wally
All Authors
Susanne Brunner, Andrea Ramspacher, Caroline Rieser, Julia Leitner, Hannah Heil, Michael Ablinger, Julia Tevini, Monika Wimmer, Andreas Koller, Josefina Piñón Hofbauer, Thomas Felder, Johann Bauer, Barbara Kofler, Roland Lang, Verena Wally
Journal association
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Abstract
Psoriasis is an inflammatory skin disease characterized by increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu and immune cell infiltration. Diacerein is an anti-inflammatory drug, modulating immune cell functions, including expression and production of cytokines, in different inflammatory conditions. Therefore, we hypothesized that topical diacerein has beneficial effects on the course of psoriasis. The current study aimed to evaluate the effect of topical diacerein on imiquimod (IMQ)-induced psoriasis in C57BL/6 mice. Topical diacerein was observed to be safe without any adverse side effects in healthy or psoriatic animals. Our results demonstrated that diacerein significantly alleviated the psoriasiform-like skin inflammation over a 7-day period. Furthermore, diacerein significantly diminished the psoriasis-associated splenomegaly, indicating a systemic effect of the drug. Remarkably, we observed significantly reduced infiltration of CD11c+ dendritic cells (DCs) into the skin and spleen of psoriatic mice with diacerein treatment. As CD11c+ DCs play a pivotal role in psoriasis pathology, we consider diacerein to be a promising novel therapeutic candidate for psoriasis.
Keywords
MANAGEMENT, DISEASE, INFLAMMATION, MICE, NEUTROPHILS, DELIVERY, MOLECULAR-MECHANISMS, RHEIN